Novo-Nordisk stock benefits from Wegovy tablet launch as obesity focus grows
Published on 09/04/2026 at 18:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo-Nordisk stock (ISIN DK0062498333) is in focus as the Danish group strengthens its obesity franchise, with its Wegovy weight-loss tablet now available in German pharmacies from September 1, 2026, and analysts underlining the company’s role in GLP-1-based therapies for obesity and type 2 diabetes.
Obesity drug Wegovy tablet reaches German pharmacies
According to a report compiled by Ground News, Wegovy in tablet form became available in German pharmacies starting September 1, 2026, after receiving European Union approval for oral use.
The article notes that Wegovy’s oral formulation, based on the active ingredient semaglutide, is prescribed for adults with obesity and aims to increase satiety, with the adult dose priced between EUR 170 and EUR 280 depending on the specific strength and treatment plan.
GLP-1 therapies keep Novo-Nordisk in the spotlight
The broader GLP-1 drug class, which includes Novo-Nordisk’s obesity and diabetes treatments, remains a central topic in clinical and market discussions. A recent Newsweek summary of a study published in Nature on September 2, 2026, reports that semaglutide extended life span in female mice when given later in life, suggesting potential aging-related indications beyond obesity and diabetes for GLP-1 therapies in the longer term, even though this remains an experimental field.
Meanwhile, an overview of weight-loss treatments discussed by the American College of Physicians highlights emerging combinations such as cagrilintide–semaglutide and other investigational agents, underscoring how Novo-Nordisk’s semaglutide-based therapies sit within a broader competitive landscape of obesity treatments that are still developing and subject to ongoing clinical evaluation.
Further information on Novo-Nordisk stock
For more background, key figures and regulatory filings on Novo-Nordisk, the following links provide a deeper overview of the company and its stock.
Wegovy and Ozempic as representative products
Wegovy, Novo-Nordisk’s obesity treatment based on semaglutide, is now available in both injectable and tablet forms and is a major revenue driver for the company’s obesity care segment. The tablet launch in Germany from September 1, 2026, adds a new option for patients who prefer oral therapy under medical supervision.
In addition, Ozempic, another semaglutide-based therapy indicated for type 2 diabetes, remains central in the company’s metabolic portfolio. Coverage of the African market notes that Ozempic competes with Eli Lilly’s Mounjaro as leading weight-loss and diabetes drugs, illustrating how Novo-Nordisk’s products are part of a global competition in treating obesity and related conditions.
Stock perspective and investor angle
Analyst commentary indicates continued interest in Novo-Nordisk stock, with a recent note describing the shares as having traded between a one-year low of DKK 224.25 and a one-year high of DKK 409.95, a range that reflects substantial gains for investors who participated in the growth of the company’s GLP-1-based therapies over the past year.
For retail investors, the key question is how the expanding use of Wegovy and related drugs in markets such as Germany and the broader European Union will translate into sustained revenue growth and profitability, especially as clinical research explores potential new indications for semaglutide and as competition intensifies in obesity and diabetes treatments.
Novo-Nordisk stock at a glance
- Company: Novo-Nordisk A/S
- ISIN: DK0062498333
- Ticker: NVO
- Trading venue: NYSE
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
